Featuring Paul Casey, Cheyenne Woods, Jonathan Kaye, Geoff Ogilvy, Tom Kalinowski, Arron Oberholser and More
ICV connects Family Offices and Fund Investors to evaluate opportunities that create a social impact beyond a financial return. There are few audiences by virtue and wealth that can advance corporate responsibility, capitalize businesses at significant levels, improve the wellbeing of humankind and influence systemic change in the world.
ICV Scottsdale 2018 will drive charitable giving to the ICV Group Cancer Breakthroughs Fund, a vital source of support for innovative research being conducted at the Sidney Kimmel Cancer Center (SKCC) at Thomas Jefferson University.
At ICV Scottsdale 2018, philanthropists will have the opportunity to play with the pros. After the tournament, we will host an Awards Ceremony and a keynote presentation by Dr. Karen Knudsen.
In the last hour, an estimated 192 people were diagnosed with cancer in the United States and every minute, someone dies from cancer in our country. At present, 1 in 2 men and 1 in 3 women in the United States will receive a cancer diagnosis, and over 15 million Americans are living with the disease.
“I walk into the building every day with full confidence that our breakthroughs and passion for providing the most advanced cancer care are making a difference.”
– Karen Knudsen, M.D.
Karen Knudsen, PhD, is Director of the Sidney Kimmel Cancer Center at Thomas Jefferson University and the Hilary Koprowski Chair of the Department of Cancer Biology of the Sidney Kimmel Medical College of Thomas Jefferson University. Jefferson has been a Philadelphia area leader in oncology research, patient treatment and cancer education services for almost 25 years. Initially a single cancer center with a staff of 30, today the Sidney Kimmel Cancer Center (SKCC) at Jefferson includes 32 hospital and practice member institutions staffed by hundreds of oncology researchers and physicians from around the globe. Dr. Knudsen is an expert in the molecular basis of hormone-dependent cancer development and progression, with a special focus on developing means to prevent or treat lethal prostate cancers. Dr. Knudsen’s research interests are dedicated to understanding the mechanisms by which genetic alterations lead to cancer progression and therapeutic bypass. Her studies identifying tumor suppressor and hormone receptor alterations have uncovered new targets for treating advanced disease, and led to development of innovative, biomarker-driven clinical trials. Dr. Knudsen is the Hilary Koprowski Professor and Chair of Cancer Biology at the Thomas Jefferson University, with joint appointments in the Departments of Urology, Radiation Oncology, and Medical Oncology. Notably, Dr. Knudsen served as the first Vice Provost for Thomas Jefferson University, overseeing and integrating basic and clinical research across all six schools at TJU. She took leave of this post in light of her appointment as Director of the Sidney Kimmel Cancer Center (SKCC). For the NCI-designated center, Dr. Knudsen was appointed in 2015 as Director. Dr. Knudsen has significant experience leading multidisciplinary efforts at SKCC and beyond, having served as Deputy Director for Research, founding Leader of the Prostate Program, and Director of Research for t Medical Oncology. Dr. Knudsen serves on multiple national boards and committees associated with both basic and clinical research, including several for the American Association for Cancer Research, the Endocrine Society, and the Prostate Cancer Foundation. She was a Senior Editor for Cancer Research from 2007-2013, is an Associate Editor for Endocrine-Related Cancer, and sits on the editorial boards of Molecular Cancer Therapeutics, the American Journal of Pathology, Molecular Endocrinology, and Oncogene. Most recently, Dr. Knudsen was appointed Editor-in-Chief of Molecular Cancer Research by AACR.
The ICV Group Cancer Breakthroughs Fund will invest in proof-of-concept studies that typically go unfunded through traditional government and industry sources. Every month, pilot grants will be awarded to Karen Knudsen, PhD, Director of the SKCC and a member of the Board Directors of the Association of American Cancer Institutes (AACI). Dr. Knudsen is one of six women in the United States to serve as director of a National Cancer Institute (NCI) designated cancer center. She is a leader among the next generation of cancer researchers and clinicians who will write the final chapters of the story that puts cancer into the history books.
All treatments that are now standard of care were once considered cutting edge, and all began with trailblazing researchers brave enough to think outside of the box, exploring frontiers that others had not even imagined.
The team of the Sidney Kimmel Cancer Center at Jefferson strives to think differently, identifying what will be obvious in ten years and developing solutions for them today. The Sidney Kimmel Cancer Center (SKCC) is home to visionary physicians and scientists who are dogged in their pursuit of high-risk, high-reward pilot research that has the potential to fundamentally transform our understanding and treatment of cancer in all its forms. However, too often these proof-of-concept studies go unfunded through traditional government and industry sources.
The ICV Group Cancer Breakthroughs Fund will change this paradigm, serving as a vital source of support for SKCC’s most promising and innovative researchers. Every month, pilot grants will be awarded by Karen E. Knudsen, PhD—Director of SKCC and the Hilary Koprowski Endowed Professor and Chair—and the SKCC Executive Council. All ICV members will be kept abreast of the latest findings and breakthroughs made possible by the Fund.
Initial Focus: Hematologic Malignancies (e.g., Leukemia and Lymphoma), Prostate Cancer, Breast Cancer, Colorectal Cancer, Car-T Cell Therapy.
Executive Summary for Donors | $3M Seed Round:
ICV Scottsdale 2018 was created after hearing the personal story of Jeff Amershadian.
A successful investment banker who raised over $150 million for various companies, Jeff departed from Wall Street after he made a promise to his sister who was dying from neuroblastoma:
He would dedicate his life to funding research for people with all terminal conditions.
Earlier this year, Jeff formed Victory Junior Tour to establish an elite national junior golf tour as a strong partner in the fight against terminal illnesses.
We are proud to have Jeff on the ICV team and to support his cause.
Troon North Golf Club
Address: 10320 E Dynamite Blvd, Scottsdale, AZ 85262
Phone: (480) 585-7700
Troon North Golf Club stands as a hallmark of the Scottsdale desert golf experience with two 18-hole courses stretching through the natural ravines and foothills in the shadows of Pinnacle Peak. Giant granite boulders lie strewn across the rugged landscape of Arizona’s Sonoran Desert, where Troon North Golf Club combines iconic golf with the visual sensation of desert landscape, providing a standard unmatched in the American Southwest.
Revered as Scottsdale’s crown jewel, the challenge, visual sensation, and special ambiance of Troon North sets the standard by which all other courses are measured. The immaculately groomed fairways, bentgrass greens and exceptional customer service create the renowned Troon Golf Experience. Troon North’s Monument and Pinnacle courses consistently rank at the top of every golfer’s must-play list. Recent course renovations by original designer and British Open Champion Tom Weiskopf have created two new layouts that bring his original concept to life. Golfers in search of the classic desert golf experience are returning to Troon North Golf Club again and again to enjoy Weiskopf’s true vision. Whether you’re playing for the first time or a regular at Troon North, these two Scottsdale courses in sunny Arizona offer golf connoisseurs the best in desert golf!
|Troon North Golf Club|
|START||END||PGA Tour Pro-Am Fundraiser Tournament|
|8:00 AM||5:00||Innovation Showcase|
|12:00 PM||5:00||Shotgun Start|
|6:30||10:00||Dinner Reception and Keynote Presentation|